BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
April 24, 2002
View Archived Issues
Xenova Enters Potential $63M Deal With Genentech For OX40
LONDON - Xenova Group plc signed a deal worth up to US$63 million plus royalties with Genentech Inc. for rights to Xenova’s preclinical OX40 program in immune inflammatory diseases. (BioWorld International)
Read More
Finnish Companies Biotie, Contral, Carbion Plan Three-Way Merger
Read More
Leukemia Case Report Gives Gene Therapy Projects Pause For Thought
Read More
Apovia Raises EUR19M Privately To Fund Vaccine Development
Read More
YM BioSciences Plans Floats On AIM, TSE To Raise Up To C$40M
Read More
Faust Pharmaceuticals Obtains $2.6M To Develop CNS Drugs
Read More
Report Says EU Biotech Trails U.S. Due To Lack Of Coordination
Read More
Molecular Skincare Spun Out To Develop Skin Disease Treatments
Read More
Other News To Note
Read More